Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers

Background: Provider implicit bias could negatively affect the doctor-patient communication. In this study, the authors measured implicit bias training in pediatric oncology providers and exposure implicit association test (IATs). They then assessed the association between IATs to race and socioeconomic status (SES) and the recommendation for the registration of clinical trials.

Methods: A prospective multisite study conducted to measure implicit bias among providers of oncology at the Hospital St. Jude Children’s Research and affiliated clinics. An IAT is used to assess the bias in the domain of race and SES. sketches of use cases to determine the relationship between bias and provider recommendation for trial registration. Data were analyzed using Student’s t test or Wilcoxon test for the comparison and the Jonckheere-Terpstra test is used for the association.

Results: Of the 105 number of the participants, 95 (90%) did not take an IAT and 97 (92%) do not have an implicit bias training before. A great effect was found for (bias towards) high SES (Cohen d, 1.93) and the European American race (Cohen d, 0.96). The majority of participants (90%) had a score sketch of 3 or 4, which indicates the recommendation for trial enrollment for part or the entire sketch. IAT and vignette scores did not significantly differ between providers on the Hospital St. Jude Children’s Research or affiliated clinics. No relationship was found between IAT and score sketches for the race (P = 0.58) or SES (P = 0.82).

Conclusions: The authors noted deficiencies prior exposure bias implicit self-assessment and training. Although providers show a preference for high SES and racial America Europe, this does not seem to affect the recommendation for registration of clinical trials that assessed by the sketch.

Through the years the ability to suppress angiogenesis has been utilized in the field of oncology. This efficiency is well documented and indications continue to grow, although the impact is often somewhat limited, as we argue in this review. Recent evidence suggests that angiogenesis inhibition may be a clinically meaningful treatment through several channels but less than the limit biomarker individual approach. The tumor microenvironment are anti-immune and anti-angiogenic drug combinations and immunotherapy has demonstrated impressive results and can change therapy in the years to come.

COVID-19 Pandemic Impact on Student and Resident Teaching and Training in Surgical Oncology

The COVID 19th pandemic has greatly changed the personal and professional interactions and behaviors worldwide. The effects of this pandemic and the measures taken have changed our health system, which in turn has affected the surgical medical education and training. In the face of constant interruption of surgical education and training during the pandemic outbreak, structured and innovative concepts and customized curriculum that is important to ensure the high quality of medical care. While efforts were made to prevent the virus from spreading, it is important to analyze and assess the impact of this crisis on medical education, surgical training and teaching in general and certainly in the field of surgical oncology.

Against this background, in this paper we introduce a practical and creative recommendations for the continuity of students and residents training and medical and surgical teaching. It includes a virtual curriculum of education, skill development classes, video-based feedback and simulation in the field of oncology surgical specialties. In conclusion, the effect COVID 19 Surgical Training and Teaching, certainly in the field of Surgical Oncology, challenging.

 Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers
Role of implicit bias in pediatric cancer clinical trials and enrollment recommendations among pediatric oncology providers

Multiomic General Oncology Database Integration in Bioconductor

Objective: Investigation of the molecular basis for the development, progress and treatment of cancer are increasingly using complementary genomic tests to collect data multiomic, but the management and analysis of the data is still complex. The cBioPortal for genomics of cancer today provides data multiomic of> 260 general studies, including The Cancer Genome Atlas (TCGA) set of data, but the integration of various types of data the remains challenging and error prone to computational methods and tools to use these resources , The latest advances in data infrastructure in Bioconductor project enables new and powerful approach to creating this integrated representation multiomic, pan-cancer database

.
Methods: We provide a set of packages R / Bioconductor to work with legacy data and data TCGA cBioPortal, with special consideration for the loading time; efficient representation in and out of memory; Analytics platform; and integrative framework, as MultiAssayExperiment.

Human VEGFR-1/Flt1-14, soluble

MBS692285-002mg 0.02mg
EUR 530

Human VEGFR-1/Flt1-14, soluble

MBS692285-5x002mg 5x0.02mg
EUR 2085

VEGFR binding peptide KH / QKRKRKKSRKKH

007-58 100 μg
EUR 158.76

VEGFR binding peptide IVLS / RKRKRKKSRYIVLS

007-59 100 μg
EUR 171.72

Rabbit Anti-Human VEGFR-1 Flt-1 (Peptide), soluble

102-PA21 100ug
EUR 240

Anti-Human VEGFR-1/Flt-1 (Peptide), soluble Antibody

102-PA21S 100 µg
EUR 126
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Human FLT-1/VEGFR-1 Control/blocking peptide #1

FLT11-P 100 ug
EUR 196.8

Human VEGFR-1/Flt1 ELISA Kit

EHV0045 96Tests
EUR 625.2

Human FLT-4/VEGFR-3 control/blocking peptide #2

FLT42-P 100 ug
EUR 196.8

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-100g 100 µg
EUR 1800

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-10g 10 µg
EUR 475

Human Vascular Endothelial Growth Factor Receptor 1 / VEGFR1 (FLT1) Peptide (OVA)

abx165607-50g 50 µg
EUR 575

Mouse FLT-4/VEGFR-3 Control/blocking peptide #1

FLT41-P 100 ug
EUR 196.8

GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human)

029-03 500 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human)

029-04 100 μg
EUR 114.48

GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human)

029-05 20 μg
EUR 267.84

Rat VEGFR- 1/ Flt1 ELISA Kit

ELA-E0147r 96tests
EUR 756

Rat VEGFR-1/Flt1 ELISA Kit

ERV0045 96Tests
EUR 625.2

Goat VEGFR-1/Flt1 ELISA Kit

EGTV0045 96Tests
EUR 625.2

Mouse VEGFR-1/Flt1 ELISA Kit

EMV0045 96Tests
EUR 625.2

Bovine VEGFR-1/Flt1 ELISA Kit

EBV0045 96Tests
EUR 625.2

Canine VEGFR-1/Flt1 ELISA Kit

ECV0045 96Tests
EUR 625.2

Rabbit VEGFR-1/Flt1 ELISA Kit

ERTV0045 96Tests
EUR 625.2

Porcine VEGFR-1/Flt1 ELISA Kit

EPV0045 96Tests
EUR 625.2

Anserini VEGFR-1/Flt1 ELISA Kit

EAV0045 96Tests
EUR 625.2

Human VEGFR1-14/Flt1-14, soluble Recombinant Protein

S01-072 20 µg
EUR 252
Description: A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

Human VEGFR1-14/Flt1-14, soluble Recombinant Protein

S01-072S 5 µg
EUR 126
Description: A human-specific splicing variant of vascular endothelial growth factor (VEGF) receptor 1 (Flt1) was discovered, producing a soluble receptor (designated sFlt1-14) that is qualitatively different from the previously described soluble receptor (sFlt1) and functioning as a potent VEGF inhibitor. sFlt1-14 is generated in a cell type-specific fashion, primarily in non-endothelial cells. Notably, in vascular smooth muscle cells, all Flt1 messenger RNA is converted to sFlt1-14, whereas endothelial cells of the same human vessel express sFlt1. sFlt1-14 expression by vascular smooth muscle cells is dynamically regulated as evidenced by its upregulation on coculture with endothelial cells or by direct exposure to VEGF. Increased production of soluble VEGF receptors during pregnancy is entirely attributable to induced expression of placental sFlt1-14 starting by the end of the first trimester. Expression is dramatically elevated in the placenta of women with preeclampsia, specifically induced in abnormal clusters of degenerative syncytiotrophoblasts known as syncytial knots, where it may undergo further messenger RNA editing. sFlt1-14 is the predominant VEGF-inhibiting protein produced by the preeclamptic placenta, accumulates in the circulation, and hence is capable of neutralizing VEGF in distant organs affected in preeclampsia. Together, these findings revealed a new natural VEGF inhibitor that has evolved in humans, possibly to protect non-endothelial cells from adverse VEGF signaling. Furthermore, the study uncovered the identity of a VEGF-blocking protein implicated in preeclampsia.

Rabbit anti VEGFR-1/Flt-1 (human)

102-PA20S 100ug
EUR 240

Mouse anti VEGFR-1/Flt-1 (#EWC) (human)

101-M24 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EIC) (human)

101-M26 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWF) (human)

101-M28 100ug
EUR 297.6

Mouse anti VEGFR-1/Flt-1 (#EWI) (human)

101-M30 100ug
EUR 297.6

Guinea Pig VEGFR-1/Flt1 ELISA Kit

EGV0045 96Tests
EUR 625.2

Mouse anti VEGFR-3/Flt-4 (#1) (human)

101-M36 100ug
EUR 297.6

Gastrin Releasing Peptide (GRP) (14-27) (Human, Porcine)

027-16 500 μg
EUR 108

Rabbit Anti-Human VEGFR-2/KDR (Peptide), soluble

102-PA19 100ug
EUR 240

Anti-Human VEGFR-2/KDR (Peptide), soluble Antibody

102-PA19S 100 µg
EUR 126
Description: VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

Mouse anti VEGFR-1/Flt-1-Biotin (#EWF) (human)

101-MBi28 50ug
EUR 297.6

Anti-Mouse VEGFR-2/Flk-1 (Peptide), soluble Antibody

103-PA19S 100 µg
EUR 126
Description: The antibody recognizes solely the endogenous soluble form of mouse vascular endothelial growth factor receptor 2, alos known as CD309, VEGFR2, KDR, protein tyrosine kinase receptor flk-1, and fetal liver kinase-1. The endogenous soluble mouse esFlk-1 generated by alternative splicing consists of the first 6 Ig-like loops followed by the unique C-terminal end: GMEASLGDRIAMP. Flk-1 is a member of the tyrosine protein kinase family, sub-family CSF-1/PDGF, that contains a single pass transmembrane receptor with a protein kinase domain and seven immunoglobulin-like domains in the extracellular region. Flk-1 is expressed at high levels in adult heart, lung, kidney, brain, and skeletal muscle; other tissues express at lower levels. Flk-1 is a receptor for VEGF-A or fully processed VEGF-C; ligand binding plays a key role in vascular development and vascular permeability.

Rabbit Anti-Mouse VEGFR-2 Flk-1 (Peptide), soluble

103-PA19 100ug
EUR 240

Mouse anti VEGFR-3/Flt-4-Biotin (#1) (human)

101-MBi36 50ug
EUR 297.6

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22AG 50ug
EUR 240

Rabbit anti VEGFR-3/Flt-4 (human)

102-PA22S 100ug
EUR 240

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-48T 48T
EUR 511.7

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-5x96T 5x96T
EUR 3472.25

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

EKC40822-96T 96T
EUR 731

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1,Flt1) Elisa Kit

EK714043 96 Wells
EUR 0.42

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1,Flt1) Elisa Kit

EK711523 96 Wells
EUR 0.18

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

EK10449 96Т
EUR 799

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-48Tests 48 Tests
EUR 325
Description: Human (Homo sapiens)

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-96Tests 96 Tests
EUR 610
Description: Human (Homo sapiens)

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

CSB-E11885h-24T 1 plate of 24 wells
EUR 198
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA kit

1-CSB-E11885h
  • Ask for price
  • Ask for price
  • Ask for price
  • 1 plate of 96 wells
  • 10 plates of 96 wells each
  • 5 plates of 96 wells each
Description: Quantitativesandwich ELISA kit for measuring Human vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-48T 48T Ask for price

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

YLA1567HU-96T 96T Ask for price

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-48Tests 48 Tests Ask for price

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-96Tests 96 Tests
EUR 388

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-48T 48T
EUR 346.8

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

GA-E0265HM-96T 96T
EUR 559.2

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

RK10114 96T
EUR 280

Human Vascuoar endothelial cell growth factor receptor 1(VEGFR-1/Flt1)ELISA Kit

QY-E00705 96T
EUR 433.2

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1;Flt1 ELISA KIT

E0248Hu-1096T 10*96T
EUR 4122

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1;Flt1 ELISA KIT

E0248Hu-48wells 48 wells
EUR 300

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1;Flt1 ELISA KIT

E0248Hu-596T 5*96T
EUR 2061

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1;Flt1 ELISA KIT

E0248Hu-96wells 96 wells
EUR 458

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-48T 48T
EUR 325
Description: Human (Homo sapiens)

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

AE43478HU-96T 96T
EUR 610
Description: Human (Homo sapiens)

Human vascular endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS703785-10x96StripWells 10x96-Strip-Wells
EUR 5140

Human vascular endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS703785-24StripWellsLIMIT1 24-Strip-Wells(LIMIT1)
EUR 275

Human vascular endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS703785-48StripWells 48-Strip-Wells
EUR 465

Human vascular endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS703785-5x96StripWells 5x96-Strip-Wells
EUR 2700

Human vascular endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS703785-96StripWells 96-Strip-Wells
EUR 655

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS9302396-10x96StripWells 10x96-Strip-Wells
EUR 6725

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS9302396-48StripWells 48-Strip-Wells
EUR 550

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS9302396-5x96StripWells 5x96-Strip-Wells
EUR 3420

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS9302396-96StripWells 96-Strip-Wells
EUR 765

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS162799-10x96StripWells 10x96-Strip-Wells
EUR 3460

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS162799-48StripWells 48-Strip-Wells
EUR 285

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS162799-5x96StripWells 5x96-Strip-Wells
EUR 1750

Human Vascuoar endothelial cell growth factor receptor 1, VEGFR-1/Flt1 ELISA Kit

MBS162799-96StripWells 96-Strip-Wells
EUR 425

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

MBS2801767-10x96StripWells 10x96-Strip-Wells
EUR 6255

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

MBS2801767-48StripWells 48-Strip-Wells
EUR 445

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

MBS2801767-5x96StripWells 5x96-Strip-Wells
EUR 3290

Human Vascular endothelial cell growth factor receptor 1 (VEGFR-1/Flt1) ELISA Kit

MBS2801767-96StripWells 96-Strip-Wells
EUR 730

Human Vascuoar endothelial cell growth factor receptor 1,VEGFR-1/Flt1 ELISA kit

201-12-0249 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Mouse Anti-Human VEGFR-1/Flt-1

MBS690002-01mg 0.1mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690002-5x01mg 5x0.1mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690109-005mg 0.05mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690109-5x005mg 5x0.05mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690355-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690355-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690361-01mg 0.1mg
EUR 450

Mouse Anti-Human VEGFR-1/Flt-1

MBS690361-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human VEGFR-1/Flt-1

MBS690384-005mg 0.05mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690384-5x005mg 5x0.05mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690483-005mg 0.05mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690483-5x005mg 5x0.05mg
EUR 1645

Mouse Anti-Human VEGFR-1/Flt-1

MBS690832-01mg 0.1mg
EUR 430

Mouse Anti-Human VEGFR-1/Flt-1

MBS690832-5x01mg 5x0.1mg
EUR 1645

Anti-Inflammatory Peptide 1

004-01 200 μg
EUR 27

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi24 50 µg
EUR 246.75
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

101-MBi30 50 µg
EUR 189
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

102-PA20 200 µg
EUR 173.25
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Anti-Human VEGFR-1/Flt-1 Antibody

102-PABi20 50 µg
EUR 157.5
Description: Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin-like extracellular domains, a single transmembrane region and an intracellular splited tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA.

Human Vascuoar Endothelial Cell Growth Factor Receptor 1, VEGFR-1 / Flt1 GENLISA ELISA

KBH0248 1 x 96 wells
EUR 286

Defensin I / Human Neutrophil Peptide-1 (HNP-1) (Human)

072-17 100 μg
EUR 370.44

Human VEGF Receptor 1 (VEGFR1, Flt1)

hAP-0001A 50ug
EUR 400

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0001 1.0mg
EUR 691.2
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

VEGFR-KDR/Flk-1 Antagonist Peptide

H-5896.0005 5.0mg
EUR 2648.4
Description: Sum Formula: C77H99N23O18S; CAS# [492444-99-2] net

GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat)

029-08 200 μg
EUR 64.8

anti- VEGFR-1/FLT-1 antibody

FNab09393 100µg
EUR 606.3
Description: Antibody raised against VEGFR-1/FLT-1

RFamide-Related Peptide 1 (RFRP-1) (Human)

048-42 500 μg
EUR 177.12

Peptide YY (PYY) (1-36)-Gly (Human)

059-07 100 μg
EUR 295.92

Human VEGFR-1/Flt-1 (D5), soluble

MBS691664-002mg 0.02mg
EUR 380

Human VEGFR-1/Flt-1 (D5), soluble

MBS691664-5x002mg 5x0.02mg
EUR 1410

Human VEGFR-1/Flt-1 (D5), soluble

MBS691669-0005mg 0.005mg
EUR 265

Human VEGFR-1/Flt-1 (D5), soluble

MBS691669-5x0005mg 5x0.005mg
EUR 890

Human VEGFR-1/Flt-1 (D3), soluble

MBS691717-002mg 0.02mg
EUR 450

Human VEGFR-1/Flt-1 (D3), soluble

MBS691717-5x002mg 5x0.02mg
EUR 1725

Human VEGFR-1/Flt-1 (D4), soluble

MBS691847-0005mg 0.005mg
EUR 310

Human VEGFR-1/Flt-1 (D4), soluble

MBS691847-5x0005mg 5x0.005mg
EUR 1110

Human VEGFR-1/Flt-1 (D3), soluble

MBS692000-0005mg 0.005mg
EUR 310

Human VEGFR-1/Flt-1 (D3), soluble

MBS692000-5x0005mg 5x0.005mg
EUR 1110

Human VEGFR-1/Flt-1 (D4), soluble

MBS692119-002mg 0.02mg
EUR 450

Human VEGFR-1/Flt-1 (D4), soluble

MBS692119-5x002mg 5x0.02mg
EUR 1725

Rabbit anti FLT1 Peptide Polyclonal Antibody

TA354699 100 µg Ask for price

Rabbit anti FLT1 Peptide Polyclonal Antibody

MBS460417-01mg 0.1mg
EUR 300

Rabbit anti FLT1 Peptide Polyclonal Antibody

MBS460417-5x01mg 5x0.1mg
EUR 1310

Nesfatin-1-Like Peptide (NLP) (Human)

009-83 100 μg
EUR 469.8

Peptide YY (PYY) (Human) - Antibody

H-059-01 100 μl
EUR 469.8

Peptide Lv (Human)

008-71 100 μg
EUR 405

SHLP1 / Small Humanin-Like Peptide 1 (Human)

018-75 100 μg
EUR 263.52

Human VEGFR-1/Flt-1 (native), soluble

MBS691505-0005mg 0.005mg
EUR 265

Human VEGFR-1/Flt-1 (native), soluble

MBS691505-5x0005mg 5x0.005mg
EUR 890

Human VEGFR-1/Flt-1 (native), soluble

MBS691991-002mg 0.02mg
EUR 380

Human VEGFR-1/Flt-1 (native), soluble

MBS691991-5x002mg 5x0.02mg
EUR 1410

[Tyr0]-RFamide-Related Peptide 1 (RFRP-1) (Human)

048-43 200 μg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-16) (Human)

027-08 1 mg
EUR 177.12

Gastrin Releasing Peptide (GRP) (1-17) (Human)

027-42 200 μg
EUR 189

Human VEGFR-1/Flt-1 (D3)-His, soluble

MBS692528-005mg 0.05mg
EUR 725

Human VEGFR-1/Flt-1 (D3)-His, soluble

MBS692528-5x005mg 5x0.05mg
EUR 2965

TCAP-1 / Teneurin C-terminal Associated Peptide-1 (Human)

020-16 100 μg
EUR 317.52

Peptide YY (PYY) (Human)

059-01 200 μg
EUR 119.88

Anti-Human VEGFR-3/FLT-4 (#1) Antibody

MBS4158541-01mg 0.1mg
EUR 920

Anti-Human VEGFR-3/FLT-4 (#1) Antibody

MBS4158541-5x01mg 5x0.1mg
EUR 3880

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (AP)

MBS6417421-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (AP)

MBS6417421-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (APC)

MBS6417422-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (APC)

MBS6417422-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (HRP)

MBS6417425-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (HRP)

MBS6417425-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (PE)

MBS6417431-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (PE)

MBS6417431-5x01mL 5x0.1mL
EUR 4120

prepro-Endothelin-1 (ET-1) Like Peptide (109-130) amide (Human)

023-11 100 μg
EUR 355.32

Peptide YY (PYY) (3-36) (Human) - Antibody

H-059-02 100 μl
EUR 604.8

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (FITC)

MBS6417424-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (FITC)

MBS6417424-5x01mL 5x0.1mL
EUR 4120

RFamide-Related Peptide 1 (RFRP-1) (Human) - FAM Labeled

FG-048-42A 1 nmol
EUR 336.96

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (Biotin)

MBS6417423-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (Biotin)

MBS6417423-5x01mL 5x0.1mL
EUR 4120

Nesfatin-1-Like Peptide(NLP) (Human) - RIA Kit

RK-009-83 125 tubes
EUR 980.64

Anti-Mouse VEGFR-1/Flt-1 Antibody

103-M31 100 µg
EUR 399
Description: Vascular Endothelial Growth Factor (VEGF or VEGF-A) family members are major mediators of vasculogenesis and angiogenesis. Specifically, biological activities attributed to VEGFs include: mitogenic activity on endothelial cells, increased permeability of endothelial cells to proteins, stimulation of monocyte migration across endothelial cells and angiogenic activity. Three VEGF family receptors have been described: Flt-1 (fms-like tyrosine kinase) also known as VEGF R1, KDR (kinase-insert domain-containing receptor) also known as Flk-1 and VEGF R2, and Flt-4 also known as VEGF R3. The three receptors contain seven extracellular immunoglobulin-like domains and share substantial sequence homology. In addition, neuropilin-1, a neuronal receptor, also acts as a co-receptor for VEGF when expressed on vascular endothelial cells, endothelial cell progenitors and monocytes. VEGF R1 is expressed primarily on endothelial cells but is also found on human peripheral blood monocytes. Through its endothelial mitogenic and hyperpermeability activities, VEGF influences a variety of immune functions related to wound healing and blood protein traffic across endothelial barriers.

Human VEGFR1 / FLT1, Fc Tag

E24PHA121 50 μg
EUR 180

Human VEGFR1 / FLT1, His Tag

E24PHA122 50 μg
EUR 225

Galanin-Like Peptide (GALP) (Human) - Antibody

H-026-51 50 μl
EUR 604.8

FLT1 Blocking Peptide

BF0131-BP 1mg
EUR 234

FLT1 Blocking Peptide

MBS9619855-1mg 1mg
EUR 380

FLT1 Blocking Peptide

MBS9619855-5x1mg 5x1mg
EUR 1650

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody

H-064-07 50 μl
EUR 238.68

GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human)

029-06 100 μg
EUR 114.48

RFamide-Related Peptide 1 (RFRP-1) (Human) - Rhodamine Labeled

FR-048-42 1 nmol
EUR 336.96

Peptide YY (PYY) (3-36)-Gly (Human) - Antibody

H-059-08 100 μl
EUR 469.8

[Cys0]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-16 100 μl
EUR 469.8

Gastrin Releasing Peptide (GRP) (Human) - Antibody

H-027-07 50 μl
EUR 238.68

Neuroendocrine Regulatory Peptide 1 (NERP-1) / prepro-VGF (281-306) (Human) - Antibody

H-076-89 100 μl
EUR 336.96

[Cys20]-Peptide YY (PYY) (3-19) (Human) - Antibody

H-059-17 100 μl
EUR 469.8

Peptide YY (PYY) (Human) - Purified IgG Antibody

G-059-01 400 μg
EUR 438.48

Peptide-Depleted Plasma (Human)

MB-099-01 2 ml
EUR 119.88

Stresscopin Related Peptide (SRP) (Human) - Antibody

H-019-27 50 μl
EUR 604.8

Recombinant Human FLT-1/VEGFR-1 Protein

RP01137 50μg
EUR 308.75

Recombinant Human FLT-1/VEGFR-1 Protein

RP02099 100μg
EUR 205.47

Mouse FLK-1/VEGFR-2 control/blocking peptide # 1

FLK11-P 100 ug
EUR 196.8

Peptide YY (PYY) (3-36) (Human)

059-02 200 μg
EUR 102.6

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 405)

MBS6417426-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 405)

MBS6417426-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 490)

MBS6417427-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 490)

MBS6417427-5x01mL 5x0.1mL
EUR 4120

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 550)

MBS6417428-01mL 0.1mL
EUR 950

FLT1 (FLT, FLT-1, VEGFR1, VEGFR-1, Vascular Endothelial Growth Factor Receptor 1) (MaxLight 550)

MBS6417428-5x01mL 5x0.1mL
EUR 4120

Methylation large sets of data provided via out-of-memory representation of the data to provide a responsive loading and analysis capabilities on machines with limited memory.

Results: We developed curatedTCGAData and cBioPortalData R / Bioconductor package to provide an integrated set of data from TCGA multiomic cBioPortal legacy database and web application programming interface using data structures MultiAssayExperiment. This suite of tools provides coordination experimental tests vary with clinicopathological the data with minimal data management burden, as demonstrated through several analysis multiomic pan-cancer and greatly simplified.

Conclusion: This representation allows analysts and developers integrated tools to apply statistical methods and a general plan for comprehensive multiomic data through user-friendly command and documented examples.

Related Posts

Leave a Reply

Your email address will not be published.